Blue Light Therapy for Actinic Keratosis

Blue light photodynamic therapy is one of the most effective office-based treatments for actinic keratoses, the rough, scaly patches caused by years of sun exposure that can progress to squamous cell carcinoma. In large multicenter trials, a single session cleared about 91% of individual lesions on the face and scalp within 12 weeks. The treatment works by pairing a topical drug that accumulates in abnormal skin cells with a specific wavelength of visible blue light, triggering a reaction that destroys those cells while largely sparing healthy tissue. But clearance rates, pain levels, and practical outcomes vary quite a bit depending on how the procedure is performed, and the details matter more than most patients realize.

Why Actinic Keratoses Need Treatment

Actinic keratoses are the most common sun-induced lesion in fair-skinned people, and they are not just a cosmetic nuisance. A large Swedish cohort study following over 17,000 patients found that people diagnosed with actinic keratoses had roughly five times the overall risk of developing skin cancer in the following decade compared with matched controls. The risk was highest for squamous cell carcinoma, where the hazard was nearly eight times greater, but basal cell carcinoma and melanoma risks were also elevated.¹ That makes actinic keratosis not just a precancerous lesion in itself but a marker that the surrounding skin has accumulated serious DNA damage. Treatments that can address both visible spots and the broader damaged field have a clear advantage, and blue light photodynamic therapy is one of the few that does both.

How the Treatment Works

The procedure starts with applying a topical solution, most commonly aminolevulinic acid (ALA), to the treatment area. ALA is a prodrug that your skin cells absorb and convert into a light-sensitive molecule called protoporphyrin IX. Damaged and precancerous cells take up far more of this molecule than normal cells do, which is the key to the treatment’s selectivity. Research on various skin cell lines has confirmed that cell death after light exposure depends more on how much of this photosensitizer accumulates in the cells than on the light dose itself.²

After an incubation period, the area is exposed to blue light, typically at a peak wavelength around 417 nanometers. The light activates the accumulated photosensitizer, which generates reactive oxygen species that destroy the abnormal cells from within. The surrounding healthy skin, which absorbed much less of the drug, sustains far less damage. Blue light has been shown to be effective both as a standalone treatment and as part of broader treatment plans for actinic keratosis and other skin conditions.³

What Clearance Rates Look Like in Practice

The landmark phase 3 trials that led to FDA approval of ALA with blue light used a long incubation protocol (14 to 18 hours) and found that 91% of individual actinic keratoses cleared by week 12, compared with just 25% in the placebo group.⁴ Those numbers were impressive, but the overnight incubation made the procedure inconvenient. More recent protocols have shortened that wait dramatically.

A randomized vehicle-controlled study found that even with incubation times as short as one hour, a single blue light session cleared roughly 36 to 57% of lesions, and a second treatment at eight weeks pushed that to 68 to 79%, comparing favorably with the longer protocols.⁵ An earlier trial specifically testing one-, two-, and three-hour incubation times found no significant difference in clearance among them: at one month, target lesion clearance was 96%, 94%, and 85% respectively, and at five months the rates held at about 87 to 94%.⁶ The practical takeaway is that shorter incubation gets you most of the benefit with fewer side effects and a visit that can fit into a lunch break rather than requiring an overnight application.

Treating the Whole Field, Not Just Individual Spots

One of blue light PDT’s genuine advantages over spot treatments like cryotherapy (freezing individual lesions with liquid nitrogen) is its ability to treat “field cancerization.” That term describes a phenomenon where the entire area of chronically sun-damaged skin harbors precancerous mutations, not just the visible rough patches. The genetic changes seen in individual actinic keratoses also exist in surrounding skin that looks clinically normal, and those subclinical areas can give rise to new lesions or even squamous cell carcinoma.⁷

When ALA is applied broadly across the forehead, scalp, or cheeks rather than dabbed onto individual spots, the photosensitizer preferentially accumulates in all abnormal cells throughout the field. After blue light activation, studies show histological improvement in the entire treated area: less severe cell abnormality, new collagen deposition, and reduced solar elastosis (the breakdown of connective tissue from chronic UV damage).⁸ This means the treatment not only clears existing lesions but helps reset the surrounding skin, reducing the likelihood of new lesions forming in the same area.

Pain During Treatment and How to Manage It

Pain is the main reason patients dread the procedure, and it is worth being honest about: conventional blue light PDT can sting, burn, or throb, sometimes intensely. How painful it is depends on the area treated, how many lesions you have, how long the drug incubated, and the light protocol used. But the good news is that newer approaches have made a substantial difference.

A bilaterally controlled randomized trial tested “simultaneous illumination,” where the blue light is turned on at the same time as the ALA is applied rather than waiting for a separate incubation period. The simultaneous side scored an average pain rating of 0.52 on a 0-to-10 scale, compared with 3.57 on the conventionally treated side.⁹ That is a dramatic drop. A comprehensive review of emerging painless PDT protocols found that short-incubation and modified light-delivery approaches achieve clearance rates comparable to conventional PDT while substantially improving tolerability and simplifying clinic workflow.¹⁰

There is a related finding on light wavelength and pain. A comparative study using red versus green light for PDT found that red light sessions were significantly more painful than green light sessions, though clearance rates were similar (about 92% and 87% respectively after three sessions).¹¹ Blue light falls between red and green on the energy spectrum. Pain seems to track with deeper tissue penetration and possibly with the total reactive oxygen species generated, so there is room for further optimization. If you have had a miserable experience with one protocol, it is worth asking your dermatologist about modified approaches before writing off the treatment entirely.

Combination Approaches That Boost Effectiveness

Researchers have been exploring ways to push clearance rates even higher by combining blue light PDT with other procedures. Two combinations stand out.

Microneedling the skin immediately before applying ALA creates tiny channels that help the drug penetrate more deeply and uniformly. In a split-face blinded trial, the side treated with microneedling before ALA and blue light achieved roughly 89% lesion reduction compared with about 70% on the PDT-only side, and the microneedled side also showed better overall cosmetic improvement in the majority of patients.¹²

Fractional carbon dioxide laser resurfacing before PDT works on a similar principle, creating microscopic columns of tissue removal that enhance drug uptake. A randomized controlled trial found that laser pretreatment pushed the complete clearance rate from about 70% to roughly 90%, even with ultrashort ALA incubation times of 15 to 30 minutes.¹³ Both approaches add cost and time, but for patients with thick, stubborn keratoses or heavy field damage, they can make a meaningful difference.

The Role of Vitamin D

This is one of those findings that surprised researchers and has practical implications patients can act on. An interventional trial measured patients’ vitamin D levels before blue light PDT for facial actinic keratoses and found that people who were vitamin D deficient had significantly worse clearance rates, averaging around 41%, compared with about 63% in patients with normal levels. When deficient patients received high-dose vitamin D supplementation before treatment, their clearance rates jumped to about 73%, significantly outperforming the unsupplemented group.¹⁴

The mechanism is not entirely worked out, but vitamin D appears to enhance the photosensitizer accumulation in abnormal cells or improve the immune response that helps clear damaged tissue after treatment. Given that many people with extensive sun damage are paradoxically vitamin D deficient (chronic sun avoidance after a skin cancer scare is common, and older adults synthesize vitamin D less efficiently), this is worth discussing with your dermatologist. Correcting a deficiency before your appointment is a low-risk intervention that could meaningfully improve your outcome.

How Blue Light PDT Compares With Other Treatments

For individual lesions, cryotherapy (liquid nitrogen) is faster and cheaper per visit, but it treats one spot at a time, cannot address field damage, and leaves more scarring. Topical chemotherapy with 5-fluorouracil (5-FU) is the other major field treatment. In a direct comparison case series, 5-FU achieved a slightly higher three-month clearance rate (93%) than daylight PDT (80%), but 5-FU caused more adverse events that lasted weeks longer, and patients preferred PDT because of the faster recovery.¹⁵ With 5-FU, the treated area typically becomes raw and crusted for three to four weeks, which many patients find socially limiting.

A pharmacoeconomic analysis found that PDT and 5-FU were among the most cost-effective treatments when accounting for adherence and adverse-effect management. Patient adherence was identified as a significant contributor to overall treatment cost, and PDT has an inherent advantage here: the treatment is administered in the office, so compliance is not an issue. Home therapies like 5-FU require weeks of daily self-application, and patients frequently stop early because of discomfort or cosmetic concerns, reducing effectiveness.¹⁶

Daylight PDT is worth mentioning as a variant. Instead of blue light in the office, patients apply the photosensitizer and then sit outdoors for a controlled period of natural light exposure. A randomized intra-individual study found daylight PDT and conventional blue light PDT produced virtually identical results at six months (about 90% versus 95% lesion reduction), with no statistically significant difference.¹⁷ Daylight PDT tends to be less painful and is increasingly popular in sunnier climates, though it is less controllable and not suitable for all weather conditions or body sites.

Special Considerations for Organ Transplant Recipients

People who have received organ transplants take immunosuppressive medications that dramatically increase their risk of skin cancer, particularly squamous cell carcinoma. Actinic keratoses progress to cancer more frequently and aggressively in this population, making effective treatment especially important. Blue light PDT has a specific role here because many other options, like surgery or imiquimod, either require intact immune function for full effect or are impractical for widespread lesions.

A study of 16 organ transplant recipients treated with PDT achieved complete clearance in all patients, though roughly a third needed a second session. All patients reported good tolerance and high satisfaction.¹⁸ A separate study in renal transplant recipients confirmed PDT’s usefulness in this population, reporting a 71% complete response rate after two sessions, with facial and scalp lesions responding better than those on the extremities.¹⁹ For transplant patients managing a constant stream of new precancerous lesions, periodic PDT sessions can be part of an ongoing surveillance-and-treatment strategy rather than a one-time fix.

The Cosmetic Bonus

This is probably the most underappreciated aspect of blue light PDT: patients frequently look better afterward in ways that go beyond clearing the rough spots. The same process that destroys precancerous cells also stimulates collagen remodeling and reduces signs of chronic photodamage, including mottled pigmentation and fine wrinkling. Clinicians noticed early on that patients treated for actinic keratoses came back looking younger, and this cosmetic improvement has been documented repeatedly.²⁰

A prospective study tested several light-activation methods combined with ALA for both actinic keratosis clearance and cosmetic improvement. Intense pulsed light (IPL) combined with blue light achieved the highest clearance (about 84%) and the best cosmetic improvement scores, while pulsed dye laser approaches showed lower improvement on both counts.²¹ The dual benefit makes PDT particularly appealing for patients who are already considering cosmetic procedures for sun-damaged skin. Insurance typically covers the medical indication (treating the keratoses), and the photorejuvenation comes along for free.

Lesions That Respond Poorly

Blue light PDT is not equally effective on all types of actinic keratoses. Thick, hyperkeratotic lesions with heavy crusting respond less well because the topical drug cannot penetrate adequately. European guidelines on PDT emphasize that the treatment has high efficacy specifically for non-hyperkeratotic lesions, and that pretreatment to reduce the thickness of crusted spots can improve outcomes.²² Curettage (gentle scraping to thin the lesion) before applying ALA is standard practice for thicker spots, and the combination therapies with fractional laser or microneedling described earlier partly address this limitation.

Location also matters. Lesions on the face and scalp respond best because the skin in those areas readily absorbs the photosensitizer. Actinic keratoses on the arms, hands, and lower legs tend to be thicker and more resistant, with some studies showing substantially lower clearance rates on extremities than on the head. If you have extensive lesions on your forearms or shins, your dermatologist may recommend topical chemotherapy or a combination approach rather than relying on PDT alone.

What Recovery Looks Like

After a blue light PDT session, the treated area will be red, swollen, and possibly tender for several days. Some patients develop crusting or superficial blistering, particularly in areas with many actinic keratoses. The reaction is essentially an exaggerated sunburn confined to cells that absorbed the photosensitizer. It peaks within the first 24 to 48 hours and gradually resolves over one to two weeks. During this time, strict sun avoidance is essential because residual photosensitizer in the skin makes you extremely susceptible to severe sunburn from even brief UV exposure.

The cosmetic downtime is real but manageable. Most people can return to work within a few days, though the redness may linger. Makeup can be applied once any crusting has healed. The severity of the reaction often correlates with the number of subclinical lesions being destroyed, so a dramatic reaction, while unpleasant, can actually be a sign that the treatment is reaching lesions you could not see. Mild reactions do not necessarily mean poor clearance, though, especially with newer short-incubation protocols designed to balance efficacy against side effects.